Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMEM132A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM132A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TMEM132A Products |
| Gene Delivery | TMEM132A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TMEM132A Products |
| Benchmark Ab | Anti-TMEM132A (Sequence of Benchmark) Recombinant positive control. |
View TMEM132A Products |
| Validator | TMEM132A siRNA Set For knockdown verification. |
View TMEM132A Products |
| Related Target A | TMEM132B Homolog counter-screening target for selectivity validation. |
View TMEM132B Products |
| Related Target B | WNT5A Synergistic pathway analysis in embryonic and tumor development. |
View WNT5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (TMEM132B/C) strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TMEM132A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEM132A therapeutics is intensifying, as its role in cellular adhesion, neurodevelopment, and tumor progression (such as in gastric cancer and glioma) becomes clearer. With major players shifting focus from traditional mAbs to targeted modalities like ADCs, the next wave of R&D is targeting highly specific tumor-associated epitopes to minimize off-target neurological effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early-stage Biotech | Solid Tumors (Gastric, Glioma) | Internalization Assay (Need high-purity ECD-Fc) |
| Monoclonal Antibody | Academic/Translational | Neurological Disorders | Binding Specificity (Need Cross-reactive Abs) |
| Gene Therapy / RNAi | Preclinical Pharms | Overexpressing Cancers | Knockdown Validation (Need siRNA sets) |